Business
Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera

Thomas Fuller | SOPA Images | Lightrocket | Getty Images
Pfizer on Monday said it would buy weight loss drugmaker Metsera in an up to $7.3 billion deal, including future payments, as it scrambles to win a slice in the booming obesity drug market.
Pfizer said it will pay an initial $47.50 a share in cash for Metsera, a nearly 43% premium to the biotech company’s Friday’s closing price of $33.32. That gives the deal an enterprise value of $4.9 billion.
The pact also includes a contingent value right worth up to $22.50 a share based on potential clinical and regulatory achievements for Metsera’s medicines, which could bring the total value to $70 a share.
The deal is expected to close at the end of the year. Shares of Metsera rose more than 60% in premarket trading on Monday, while Pfizer’s stock rose more than 1%.
The move comes after a string of setbacks for Pfizer in the obseity space. The pharmaceutical giant struggled to develop its own lead obesity drug candidate, danuglipron, before deciding to scrap it entirely in April due to safety concerns. Pfizer also discontinued a different once-daily pill in June 2023 due to elevated liver enzymes in patients who received it.
Pfizer has earlier-stage obesity drugs in its pipeline that work in different ways, but the company has faced mounting investor pressure to accelerate its push into the market.
The opportunity could be huge. Some analysts expect the weight loss drug space could be worth roughly $100 billion by the 2030s, with room for new rivals to compete with popular injections from Eli Lilly and Novo Nordisk.
Metsera, founded in 2022, brings a pipeline of both oral and injectable treatments with different targets that the company had picked up through its own licensing and acquisition deals. That includes a GLP-1 drug called MET-233i, which helped patients lose up to 8.4% of their weight in 36 days in a small, early-stage trial. Metsera is developing that treatment as a potential once-monthly injectable, meaning that patients can take it less frequently than existing weekly injections.
Metsera’s pipeline also includes a monthly drug targeting a hormone called amylin, along with two oral GLP-1 candidates “expected to begin trials imminently,” Pfizer said in a release.
“The proposed acquisition of Metsera aligns with our focus on directing our investments to the most impactful opportunities and propels Pfizer into this key therapeutic area,” Pfizer CEO Albert Bourla said in a statement. “We are excited to apply our deep cardiometabolic experience and manufacturing and commercial infrastructure to accelerate a portfolio that includes potential best-in-class injectables.”
In a note on Monday, Leerink Partners analyst David Risinger said the firm estimates Metsera’s obesity candidates have the potential to generate more than $5 billion in combined peak annual sales. In a separate note on Monday, JPMorgan analyst Chris Schott said Metsera’s experimental drugs “should accelerate” Pfizer’s entry into the market.
The New York-based Metsera went public this year in one of the biggest biotech listings of 2025. It is among several companies racing to develop next-generation obesity treatments following the success of weekly injections such as Eli Lilly’s obesity drug Zepbound and Novo Nordisk’s rival Wegovy.
Business
Full list of Bodycare shops to shut this week after failing to secure a buyer

All remaining Bodycare shops will shut this week, after the beauty chain’s administrators failed to secure a buyer to keep it on Britain’s high streets.
The chain is set to vanish from Britain’s high streets, with administrators confirming the closure of all 56 remaining stores, leading to approximately 450 redundancies. The beauty retailer entered administration earlier this month, failing to secure a buyer for its UK chain.
Advisory firm Interpath, overseeing the administration, stated that this inability to find a purchaser necessitated the difficult decision to cease trading. Bodycare, established in Lancashire in 1970, specialised in beauty products, fragrances, and various bathroom essentials.
Its outlets were a familiar sight in shopping centres and high streets nationwide. The final closures are anticipated by Saturday, affecting all 444 employees across the stores, who will now face redundancy.
These are the locations of the 56 Bodycare stores that will close this week:
Ashton-under-Lyne, Greater Manchester
Banbury, Oxfordshire
Barnsley, South Yorkshire
Barrow-in-Furness, Cumbria
Bedford, Bedfordshire
Blackburn, Lancashire
Blackpool, Lancashire
Braehead, Scotland
Bridgnorth, Shropshire
Burnley, Lancashire
Bury, Greater Manchester
Chorley, Lancashire
Clitheroe, Lancashire
Darlington, Co Durham
Derby, Derbyshire
Dundee, Scotland
Halifax, West Yorkshire
Hereford, Herefordshire
Hinckley, Leicestershire
Irvine, Scotland
Keighley, West Yorkshire
Kendal, Cumbria
Kings Heath, West Midlands
Lancaster, Lancashire
Leeds, West Yorkshire
Leicester, Leicestershire
Leigh, Greater Manchester
Liverpool, Merseyside
Livingston, Scotland
Luton, Bedfordshire
Manchester, Greater Manchester
Merry Hill, West Midlands
Metrocentre, Gateshead, Tyne and Wear
Middlesbrough, North Yorkshire
Mold, Wales
Newcastle, Tyne and Wear
Nuneaton, Warwickshire
Oldham, Greater Manchester
Pontefract, West Yorkshire
Poulton-le-Fylde, Lancashire
Preston, Lancashire
Rugby, Warwickshire
Sheffield, South Yorkshire
Solihull, West Midlands
Sunderland, Tyne and Wear
Sutton Coldfield, West Midlands
Swindon, Wiltshire
Telford, Shropshire
Thurrock, Essex
Trowbridge, Wiltshire
Wakefield, West Yorkshire
Walthamstow, north-east London
Warrington, Cheshire
Washington, Tyne and Wear
Wellingborough, Northamptonshire
Wolverhampton, West Midlands
Business
Diwali Muhurat Trading 2025: NSE, BSE Announce Timings, Different From Last Year

Last Updated:
The exchange announced that the pre-opening session will take place from 1:30 pm to 1.45 pm

The market will remain closed for regular trading on Diwali, but a special trading window will be open for one hour.
Stock exchanges NSE and BSE will conduct a special Muhurat trading session on Tuesday, October 21, to mark the festival of Diwali, the bourses announced on Monday.
The symbolic trading session will be held between 1:45 pm and 2:45 pm, the stock exchanges said in separate circulars.
Last year, the special Muhurat trading session was held from 6 pm to 7 pm.
The new session also marks the beginning of a new Samvat (Vikram Samvat 2082) — the Hindu calendar year that starts on Diwali — and it is believed that trading during the ‘Muhurat’ or auspicious hour brings prosperity and financial growth for the stakeholders.
The market will remain closed for regular trading on Diwali, but a special trading window will be open for one hour.
The exchange announced that the pre-opening session will take place from 1:30 pm to 1.45 pm.
Market analysts noted that Diwali is considered an auspicious occasion to begin new ventures, and many investors believe participating in the Muhurat trading session brings prosperity throughout the year.
However, with the trading window limited to just an hour, the markets often witness heightened volatility. Analysts added that the significance of the session lies more in its symbolic value than in immediate profitability.
Trading would take place across various segments like equity, commodity derivatives, currency derivatives, equity futures & options, and securities lending & borrowing (SLB) in the same time slot, according to separate circulars issued by the bourses. PTI SP SHW
(This story has not been edited by News18 staff and is published from a syndicated news agency feed – PTI)
September 22, 2025, 20:34 IST
Read More
Business
Gold Prices Hit Record Rs 1.11 Lakh per 10 Grams, Silver Tops Rs 1.33 Lakh/kg As Safe-Haven Demand And Weak Rupee Push Bullion To All-Time Highs

New Delhi: Gold prices in India climbed to unprecedented levels on Monday, with futures trading touching Rs 1,11,750 per 10 grams — a fresh all-time high. The December delivery contract on the Multi Commodity Exchange (MCX) rose by Rs 799 (about 0.72 percent) to reach this peak, as investors reacted to global cues including expected US inflation data and remarks from Federal Reserve officials.
Silver followed suit, with brisk gains across delivery contracts. The March silver futures, for example, surged by Rs 2,446 (nearly 1.86 percent ) to settle at Rs 1,33,582 per kilogram. The December silver contract also breached previous highs, jumping by Rs 2,473 (almost 1.9 percent) to hit Rs 1,32,311/kg.
Analysts believe several factors are pushing precious metal prices upward:
A weaker Indian rupee, which makes imports costlier.
Geopolitical tension and global macroeconomic uncertainty, leading investors to seek safe-haven assets like gold.
Inflation expectations in the US, along with signals from the Fed about possible future rate cuts.
Industrial demand boosting silver — especially for applications in solar panels, electronics, EVs and other green technologies.
Some experts are now forecasting that silver might push toward Rs 1,40,000–Rs 1,50,000 per kg in the near term, depending on supply trends and ongoing demand.
For now, the current price levels mark a new benchmark in the bullion market — signalling both investor caution and eagerness, as global and domestic forces combine to reshape what was already a strong run upward.
-
Tech1 week ago
How to Switch to Google Fi
-
Tech1 week ago
The Top 11 Protein Powders, According to My Stomach
-
Tech1 week ago
The Hypershell Pro X Exoskeleton Made My Hikes Feel Easier—Then I Checked My Stats
-
Fashion1 week ago
UK retailer ASOS & ITF sign deal to protect transport workers’ rights
-
Tech1 week ago
The MOTIF Hand: A tool advancing the capabilities of previous robot hand technology
-
Tech7 days ago
How AI Is Upending Politics, Tech, the Media, and More
-
Fashion1 week ago
GHG emissions hit record high in 2024 despite declines in EU, Japan
-
Fashion7 days ago
India’s new GST makes artisan-made ethnic wear costlier